Understanding why psychedelics alter perception at a mechanistic level has implications beyond ceremonial use — it informs therapeutic development, sensory processing disorders, and why different psychedelics produce qualitatively distinct experiences. New neuroimaging data on mescaline, one of the oldest-used psychedelics yet among the least studied neurobiologically, offers a surprisingly specific answer involving an underappreciated brain region.
Using pharmacological and resting-state BOLD fMRI in awake rats, this study provides the first comprehensive neurobiological fingerprint of mescaline, a 5-HT2A serotonin receptor agonist. Acutely, mescaline produced selective suppression of cerebellar BOLD signal — reducing local metabolic activity — while paradoxically generating global hyperconnectivity in resting-state networks. The cerebellum specifically formed enhanced functional connections with the hippocampus, thalamus, somatosensory cortex, and midbrain. Mescaline also abolished normal reward-associated BOLD responses to olfactory stimuli, and produced frequency-selective effects on pre-pulse inhibition: boosting acoustic gating at 4 kHz (+27.6%) and 20 kHz (+27.3%) while impairing it at 12 kHz (−16.4%).
This cerebellar-centric mechanism is notably distinct from profiles reported for LSD and psilocybin, which tend to primarily disrupt default mode network and thalamocortical connectivity. The cerebellum has historically been underestimated in perceptual and cognitive neuroscience, but growing evidence implicates it as a critical sensory timing and prediction-error filter. The mescaline data suggest that suppressing cerebellar local activity while simultaneously amplifying its long-range connectivity may be the mechanism by which unfiltered or mistimed sensory signals flood cortical circuits — a plausible substrate for psychedelic-typical perceptual distortions and synesthesia. Key limitations are significant: this is an animal-only study, awake-rat fMRI introduces motion artifacts, and translating connectivity maps to human subjective experience remains speculative. Still, by distinguishing mescaline's pharmacodynamic signature from other classic psychedelics, the findings are genuinely incremental for psychedelic neuroscience and may inform which compounds are better suited for specific therapeutic targets.
